Virologic non-suppression determinants in Kenyan HIV positives: A cross-sectional study

Despite the substantial scale-up in treatment coverage and viral load monitoring, virologic non-suppression persists among people living with HIV in Kenya. In this study, we describe the extent of virologic non-suppression and identify associated factors in people living with HIV under combination antiretroviral therapy and routine viral load monitoring in Kenya. We conducted a retrospective cross-sectional study on routinely collected viral load data generated from January 2016 to June 2025. Mean, median, and proportions were used to describe the variables, and logistic regression analysis was performed to determine the factors associated with virologic non-suppression. The overall virologic non-suppression rate was 7.1%. Increased odds of virologic non-suppression were associated with male sex (adjusted odds ratio [aOR] = 1.35, 95% confidence interval [CI]: 1.33-1.37, P < .001), children (aOR = 2.19, 95% CI: 2.14-2.24, P < .001), adolescents (aOR = 1.77, 95% CI: 1.73-1.81, P < .001), Protease inhibitor based regimen (aOR = 1.12, 95% CI: 1.10-1.15, P < .001), and persistent low-level viremia (aOR = 1.46, 95% CI: 1.24-1.70, P < .001). Longer duration on treatment (73+: aOR = 0.95, 95% CI: 0.93-0.97, P < .001) and Integrase inhibitor-based regimen (aOR = 0.29, 95% CI: 0.28-0.29, P < .001) were protective of non-suppression. Virologic non-suppression was common in the study population. Sex, age, duration on treatment, regimen class, and geographical location were significantly associated with non-suppression. Each of these variables presents opportunities for interventions to help achieve the UNAIDS 95-95-95 goals.

Authors

Institutions

Publication Details

Journal
Medicine
Published
2026-11-13
DOI
https://doi.org/10.1097/md.0000000000051578
Primary Topic
HIV/AIDS Research and Interventions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Virologic non-suppression determinants in Kenyan HIV positives: A cross-sectional study

Matilu Mwau, Rosaline Wanjiru Macharia, Jane Mawia Kilonzo, Martin M. Mulinge et al.
1 links
Medicine
HIV/AIDS Research and Interventions
article

Virologic non-suppression determinants in Kenyan HIV positives: A cross-sectional study

Matilu Mwau, Rosaline Wanjiru Macharia, Jane Mawia Kilonzo, Martin M. Mulinge, Evans Omollo Ochieng’, Nancy Kagendi Kibui, David Kibet Boyo
article en

Abstract

Despite the substantial scale-up in treatment coverage and viral load monitoring, virologic non-suppression persists among people living with HIV in Kenya. In this study, we describe the extent of virologic non-suppression and identify associated factors in people living with HIV under combination antiretroviral therapy and routine viral load monitoring in Kenya. We conducted a retrospective cross-sectional study on routinely collected viral load data generated from January 2016 to June 2025. Mean, median, and proportions were used to describe the variables, and logistic regression analysis was performed to determine the factors associated with virologic non-suppression. The overall virologic non-suppression rate was 7.1%. Increased odds of virologic non-suppression were associated with male sex (adjusted odds ratio [aOR] = 1.35, 95% confidence interval [CI]: 1.33-1.37, P < .001), children (aOR = 2.19, 95% CI: 2.14-2.24, P < .001), adolescents (aOR = 1.77, 95% CI: 1.73-1.81, P < .001), Protease inhibitor based regimen (aOR = 1.12, 95% CI: 1.10-1.15, P < .001), and persistent low-level viremia (aOR = 1.46, 95% CI: 1.24-1.70, P < .001). Longer duration on treatment (73+: aOR = 0.95, 95% CI: 0.93-0.97, P < .001) and Integrase inhibitor-based regimen (aOR = 0.29, 95% CI: 0.28-0.29, P < .001) were protective of non-suppression. Virologic non-suppression was common in the study population. Sex, age, duration on treatment, regimen class, and geographical location were significantly associated with non-suppression. Each of these variables presents opportunities for interventions to help achieve the UNAIDS 95-95-95 goals.

MedicineVol. 105(46)
University of Nairobi (KE), Kenya Medical Research Institute (KE)
Good health and well-being
HIV/AIDS Research and Interventions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon